

Research

Hepatitis B mother-to-child transmission in the Eastern Region of Ghana: a cross-sectional pilot study



Thomas Hambridge^{1,&}, Yvonne Nartey^{1,2}, Amoako Duah³, Amelie Plymoth¹

¹Department of Medical Epidemiology and Biostatistics (MEB), Karolinska Institutet, Stockholm, Stockholm County, Sweden, ²Department of Medicine and Therapeutics, Cape Coast Teaching Hospital, Cape Coast, Central Region, Ghana, ³Department of Medicine, St. Dominic's Hospital, Akwatia, Eastern Region, Ghana

[&]Corresponding author: Thomas Hambridge, Department of Medical Epidemiology and Biostatistics (MEB), Karolinska Institutet, Stockholm, Stockholm County, Sweden

Key words: Hepatitis B, mother-to-child transmission, Ghana, infectious disease, vaccination

Received: 30/09/2018 - Accepted: 14/05/2019 - Published: 17/07/2019

Abstract

Introduction: hepatitis B is a major health concern in Ghana, where prevalence of the virus remains high and most chronic patients are infected during childhood or at birth. This study aimed to determine the prevalence and main factors associated with mother-to-child transmission of hepatitis B in the context of Ghana. **Methods:** in this cross-sectional pilot study, we tested infants born to hepatitis B positive mothers at a hospital in the Eastern Region of Ghana to determine the prevalence of mother-to-child transmission. A questionnaire was completed by hepatitis B positive mothers to investigate the association between factors surrounding the birth of the child and whether transmission had occurred. These factors were analyzed independently using Fisher's exact test. To investigate the relationship between mother's age at the time of delivery and viral transmission, a univariate logistic regression analysis was performed. **Results:** the prevalence of mother-to-child transmission was 5.9%, with 51 hepatitis B positive mothers included in the study and three infants testing positive. A majority of infants received the standard hepatitis B vaccination schedule (96.1%) while two-thirds received the birth dose. There was no significant association observed between the clinical interventions reported in the study and mother-to-child transmission. No significant association was observed between the age of the mother at the time of delivery and viral transmission (OR: 1.077, 95% CI: 0.828 - 1.403, $p = 0.58$). Viral marker testing during pregnancy was absent in the population and could not be reliably assessed. **Conclusion:** there was a low prevalence of HBV mother-to-child transmission observed despite a clear absence of viral marker and viral load testing. It is recommended that viral profile analysis is performed for hepatitis B positive pregnancies to identify high risk cases.

Pan African Medical Journal. 2019;33:218. doi:10.11604/pamj.2019.33.218.17242

This article is available online at: <http://www.panafrican-med-journal.com/content/article/33/218/full/>

© Thomas Hambridge et al. The Pan African Medical Journal - ISSN 1937-8688. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Introduction

Hepatitis B virus (HBV) remains a global health concern, with an estimated 2 billion people serologically positive worldwide [1]. According to a recent report from the World Health Organization (WHO), approximately 257 million individuals were chronically ill with the disease in 2015 [2]. Moreover, global mortality from hepatitis B is increasing, accounting for up to 1.2 million deaths per year [3]. In high prevalence areas, HBV infection is typically acquired during childhood or through perinatal transmission [4]. Mother-to-child transmission (MTCT) can refer to three separate modes of transmission: during pregnancy (intrauterine infection); during delivery; or postpartum horizontal transmission through breastfeeding or daily contact [5]. It is estimated that 90% of infected newborns are likely to develop chronic hepatitis B (CHB) and are at much higher risk of developing liver disease, including cirrhosis and hepatocellular carcinoma during their adulthood [6-9]. Thus, taking measures to stop MTCT is essential for reducing the burden of CHB. In Ghana, chronic infection with HBV is considered highly endemic. In a recent systematic review of 30 studies across all 10 regions, Ofori-Asenso & Agyeman found that hepatitis B surface antigen (HBsAg) seropositivity was 12.3% [10]. This figure is more or less in line with a systematic review conducted by Schweitzer *et al.* which estimated that the prevalence of chronic HBV in Ghana was 12.9% [11]. Ghana introduced hepatitis B vaccination (DPT-Hib-HBV pentavalent vaccine) as part of the Expanded Programme on Immunization (EPI) in 2002, recommending administration of the vaccine at 6, 10 and 14 weeks. WHO also recommends administration of the HBV vaccine within 24 hours of birth. However, birth dose coverage remains low at 39% globally and Ghana is one of several countries yet to adopt this policy at a national level [12]. Moreover, the WHO Western Pacific Region highlighted in a recent report that post-vaccination serologic testing (PVST) for HBsAg and antibodies could be used to help evaluate infant seroprotection following immunization [13].

In addition to the birth dose vaccine, it is crucial to identify infants who are at higher risk of perinatal transmission to administer hepatitis B immune globulin (HBIG), which has previously been shown to be an effective form of post-exposure prophylaxis [14, 15]. Hepatitis B e antigen (HBeAg) status and elevated viral load during pregnancy are established risk factors for perinatal transmission [16-18]. The rates of HBeAg seroconversion in chronically infected individuals, i.e. the clearance and development of antibodies against the antigen, increase with age [9]. This means that mother's age during gestation could

also be an important risk factor for transmission. Although there has been extensive research into the factors influencing HBV mother-to-child transmission, there has been limited focus on the context of West Africa and specifically Ghana. This is particularly relevant given the high prevalence of HBV genotype E in the region, a genetic variant of the virus which requires further investigation. Compared to other genetic variants of HBV, transmission of genotype E appears to be predominantly horizontal in endemic areas [19-21]. Moreover, HBeAg seroconversion likely occurs before child-bearing age in Ghana, where genotype E is predominant and may result in lower rates of MTCT compared to other countries. The main objective of this cross-sectional pilot study was to determine the prevalence of HBV mother-to-child transmission at a hospital in the Eastern Region of Ghana by testing children when they were brought into the clinic with their mothers. We also aimed to assess the clinical interventions employed and sought to identify the main factors associated with HBV mother-to-child transmission in this setting. These preliminary findings will be used to develop a larger prospective cohort study to be conducted at multiple sites throughout Ghana.

Methods

Study area

The study was conducted at St Dominic's Hospital, Akwatia in the Eastern Region of Ghana. There are roughly 2200 babies born at St Dominic's hospital each year and this site was selected based on the availability of accessible maternal health records and contact details for the mothers. The hospital is funded by donor and government contributions and does not have any specific protocols for handling cases of HBsAg positive pregnancies. They follow the national policy regarding birth dose vaccine and HBIG, both of which must be paid for out-of-pocket.

Study population and subject selection

Convenience sampling of maternal health records was used to retrospectively identify mothers who were HBsAg positive during pregnancy, with a child aged between 6-24 months at the time of recruitment. At St. Dominic's Hospital, HBsAg positive cases are recorded within the first days of visiting the antenatal care clinic until birth. Using these records, a list was compiled which consisted of 51 eligible mothers who gave birth within the specified time period, with

their child aged 6-24 months. Cases were excluded where infants were outside of the study age range at the time of testing, as well as mothers who declined to provide consent. Study participants were enrolled from February 2018 to April 2018.

Hepatitis B testing

Hepatitis B tests were performed by a physician using InTec HBsAg Rapid Test Strips of whole blood. According to the manufacturer, test strips have a sensitivity of 99.4% and specificity of 99.8%. The InTec HBsAg Rapid Test Strips were manufactured by Intec Products Inc. in Xiamen, China. Whole blood from a finger prick was placed on the test strip, and the result was read after 15 minutes according to the manufacturer's instructions. The test works on the principle of lateral diffusion, where the formation of an antibody-antigen complex results in visible bands which are considered positive. Positive test results in infants were confirmed by laboratory analysis. The results from prospective HBsAg testing were compared with responses from a questionnaire completed by the mother, which included questions relating to the birth context and interventions.

Study questionnaire

A one-page questionnaire was completed by the mothers and responses were a combination of personal recollection and information retrieved from government issued maternal and child health records. The variables included in the questionnaire were selected based on evidence from previous studies in different settings. These included mother's age at the time of delivery, the birth location, the birth type, the infant's vaccination status, HBIG administration, mother's HBeAg status, viral load measurements, PVST and whether antiviral treatment was administered during pregnancy [9, 13-18].

Data analyses

Questionnaire responses and test results from hepatitis B positive mothers and their children ($n = 51$) were entered into Microsoft Excel 2007 and imported into Statistical Package for Social Sciences (SPSS) version 25 for analysis. Descriptive analysis was performed to assess the questionnaire response rates. This analysis was also intended to measure the scope of viral marker testing and interventions in HBsAg positive pregnancies to evaluate how cases are managed in the clinic. Categorical data was expressed here as a number and percentage.

Aside from mother's age, infant's age and viral load, all of the responses collected from the questionnaire were categorical variables and analyzed independently as unpaired data. The outcome used in the analysis of questionnaire responses was whether the child was HBsAg positive, i.e. whether mother-to-child transmission had occurred. The outcome was binary categorical. The data was cross-tabulated and analyzed using Fisher's exact test for independence. All p-values for this test were two-tailed with $p < 0.05$ considered significant.

To investigate the relationship between incremental change in mother's age at time of delivery and viral transmission, a univariate (unadjusted) logistic regression analysis was performed. The outcome used was whether the infant tested positive for HBsAg. Odds ratio (OR) with 95% confidence intervals (CI) are presented. The p-values for the univariate logistic regression were two-tailed with $p < 0.05$ considered significant. In order to obtain a valid analysis for multivariate logistic regression, we would need to observe approximately 10 outcome events per variable included [22]. As a result, this pilot study was not sufficiently powered to adjust for covariates.

Ethical considerations

The study was approved by the Institutional Ethical Review Board at St Dominic's Hospital and local permission was obtained prior to recruitment. The details and reasons for the study were clearly explained in a language that was understood by participants. Information was provided including risks, benefits and any possible complications. Consenting mothers were asked to visit the clinic with their child for HBsAg testing and to complete the study questionnaire.

Results

General characteristics

A total of 51 hepatitis B positive mothers were included in the study. Mother's age in the sample population ranged from 23 to 40 years. The average age was 31.2 years and only two mothers recruited into the study were under the age of 25. The age of their infants who were tested for HBsAg ranged from 6 to 22 months, with an average age of 13.5 months. All deliveries took place within a hospital setting with no home births observed. The percentage of caesarean sections was

37.3% and a majority of births were vaginal deliveries (62.7%) (Table 1).

Clinical interventions

There was a high vaccination rate observed (96.1%), with only two of the infants receiving no HBV vaccine at all. Two-thirds of infants received the WHO recommended birth dose administered within the first 24 hours. Moreover, a majority of infants who were vaccinated received the pentavalent EPI three dose vaccine schedule at 6, 10 and 14 weeks of age in addition to the birth dose (59.2%). Despite the high vaccination rates, none of the infants underwent PVST to evaluate seroprotection status. More than half of the infants (60%) received single dose HBIG at birth to provide further protection. Only one mother received antiviral therapy during pregnancy and her HBV DNA was measured, which was less than 20 IU/ml. There were no HBeAg tests performed during pregnancy. However, HBeAg was tested on three occasions post-delivery, with all three tests returning positive results (Table 2, Table 3).

Factors associated with HBV mother-to-child transmission

To investigate mother's age at the time of delivery as a potential factor for transmission, a univariate logistic regression was performed with no covariates included in the model. This showed no significant association (OR: 1.077, 95% CI: 0.828 - 1.403, $p = 0.58$). The remaining binary study variables were analyzed using Fisher's exact test of independence. Prevention of MTCT through administration of HBIG at birth was not significant ($p = 0.06$), despite no transmission observed in any of the 30 cases that received the prophylaxis. None of the other study variables, including birth type, any vaccination, birth dose vaccine or antiviral therapy during pregnancy demonstrated significance using this statistical method. Data collected from the study questionnaire was insufficient to test for an association between HBeAg status or DNA viral load and risk of transmission (Table 4).

Discussion

This formative study aimed to determine the prevalence of HBV mother-to-child transmission at a single site in the Eastern Region of Ghana as a pre-trial for a larger study. The main factors associated with MTCT were investigated quantitatively, while the responses from the questionnaires were used to evaluate how HBsAg positive

pregnancies were managed in the clinic. Given that the estimated national prevalence of individuals with CHB is approximately 12.3% in Ghana [10], the finding that only three of the 51 infants were HBsAg positive in this study was somewhat lower than anticipated. This is an important observation and appears to align more closely with the 8.3% HBV maternofetal transmission rate in chronic carriers observed by Candotti *et al.* in Kumasi [23] and the 8.7% seroprevalence reported by Amidu *et al.* in the nearby Ashanti region [24]. In most cases, when an adult is exposed to HBV, the virus will be cleared completely with no long-term manifestations. Conversely, a majority of those exposed to the virus during childhood when the immune system is immature are likely to develop chronic infection [17]. If the prevalence of HBV mother-to-child transmission is in fact lower than expected in Ghana, this may support the argument that early horizontal transmission through direct contact is a major source of newly acquired chronic HBV infections in West Africa [23, 25, 26]. It should be highlighted here that we used a maximum inclusion age limit of 24 months to minimise false negatives while maintaining the assumption that any positive tests observed were the result of MTCT rather than early horizontal transmission. This assumption may therefore be a limitation of the study.

Although this pilot study was unable to demonstrate significant protection against HBV mother-to-child transmission with HBIG ($p = 0.06$), this intervention has been previously shown to be an effective form of prevention [14, 15]. The issue with the single-dose HBIG is that it is an expensive form of post-exposure prophylaxis and is not covered by the National Health Insurance Scheme (NHIS) in Ghana. There was also no significant association observed using univariate logistic regression of mother's age. There is rationale to explore this further with a larger sample size, as younger women are more likely to be in the HBeAg positive and high viral load phase known as 'immune tolerance' [1]. It has been proposed that HBeAg seroconversion of HBV genotype E occurs at a much younger age than other genotypes, although this may still be an important factor to consider in younger women of childbearing age who have not yet seroconverted [27].

The vaccination rates observed at St. Dominic's Hospital were encouraging, at 96.1% in total. A further 66.7% of all infants received the WHO recommended birth dose and only two received no HBV vaccine at all. The study was unable to demonstrate a significant association between vaccination and MTCT. Although speculative given the limited sample size, there is reason to hypothesise that sustained seroprotection may play a role in transmission risk,

particularly with a potential lack of cross protection towards the endemic HBV genotype E [17, 28]. This is currently an area of research interest in Ghana as vaccination uptake continues to increase and should be further investigated in the follow-up phase. It could also put a greater importance on PVST to ensure non-responders receive full vaccine protection. None of the infants in this study underwent PVST to evaluate seroprotection status.

One of the most important observations in this study was the absence of HBeAg and viral load testing. HBV viral profile testing can be performed locally to determine HBeAg status of infected mothers and may be used as a surrogate marker for high viral load. It has been consistently demonstrated in previous studies conducted in different settings that a positive HBeAg status and high viral load during pregnancy are strongly associated with elevated risk of MTCT [16-18]. In fact, of the three cases that performed HBeAg testing after delivery, each was positive for this marker and MTCT was observed in two of the three cases. Although these factors could not be reliably assessed here due to the lack of tests performed, the fact that no HBeAg test was performed and only one viral load was measured prior to delivery is a finding in itself. Moreover, they could represent key stages in the pregnancy and perinatal period which require further intervention to reduce the occurrence of MTCT in Ghana.

Conclusion

There was a low prevalence of HBV mother-to-child transmission observed despite a clear absence of viral marker testing and subsequent intervention. Nevertheless, it is strongly recommended that positive HBsAg tests in Ghana are followed up with a viral profile analysis as an effective method of identifying high risk cases.

What is known about this topic

- In Ghana, chronic hepatitis B is considered highly endemic, with an estimated HBsAg seroprevalence of 12.3% across all 10 regions;
- High viral load and positive HBeAg status during pregnancy are associated with an increased risk of mother-to-child transmission;
- In addition to birth dose vaccination, the risk of HBV mother-to-child transmission from a HBsAg positive mother to infant can be effectively reduced through post-exposure prophylaxis in the form of HBIG.

What this study adds

- The prevalence of mother-to-child transmission was 5.9%;
- In this setting, HBeAg and viral load testing are not routinely performed on mothers who test positive for HBsAg during pregnancy;
- More than half of the families (60%) in this study opted for single dose HBIG at birth to provide further protection against transmission.

Competing interests

The authors declare no competing interests.

Authors' contributions

TH, YN, AD and AP contributed to the study design. AD was responsible for enrolling and recruiting mothers and their infants at the study site. TH and AD tested the infants and collected questionnaire data from the mothers. TH and YN performed the statistical analysis. AD and AP contributed materials and analysis support. TH wrote the paper with input from YN, AD and AP. All authors have read and agreed to the final manuscript.

Acknowledgments

We wish to express a special thanks to the staff at St. Dominic's Hospital for their warm hospitality while conducting our research there and to all of the families who participated. We are also grateful to Professor Lewis Roberts at the Mayo Clinic and to the wider research team for all of their support and contributions.

Tables

Table 1: general characteristics of the mothers and infants included in the study and the birth context, n = 51

Table 2: proportion of infants who were vaccinated and received prophylactic interventions, as well as mothers who received antiviral therapy during pregnancy

Table 3: hepatitis B viral marker testing rates and results of mothers during pregnancy

Table 4: contingency tables and Fisher's exact test of factors related to HBV mother-to-child transmission

References

1. McMahon BJ. Natural History of Chronic Hepatitis B. *Clin Liver Dis.* 2010;14(3):381-396. **PubMed | Google Scholar**
2. World Health Organization. Global Hepatitis Report. 2017. **Google Scholar**
3. Spearman CW, Afihene M, Ally R, Apica B, Awuku Y, Cunha L *et al.* Hepatitis B in sub-Saharan Africa: strategies to achieve the 2030 elimination targets. *Lancet Gastroenterol Hepatol.* 2017;2(12):900-909. **PubMed | Google Scholar**
4. Franco E, Bagnato B, Marino MG, Meleleo C, Serino L, Zaratti L. Hepatitis B: epidemiology and prevention in developing countries. *World J Hepatol.* 2012 Mar 27;4(3):74-80. **PubMed | Google Scholar**
5. Ma L, Alla NR, Li X, Mynbaev OA, Shi Z. Mother-to-child Transmission of HBV: review of current clinical management and prevention strategies. *Rev Med Virol.* 2014 Nov;24(6):396-406. **PubMed | Google Scholar**
6. Keeble S, Queded J, Barker D, Varadarajan A, Shankar AG. Immunization of babies born to HBsAg positive mothers: an audit on the delivery and completeness of follow up in Norfolk and Suffolk, United Kingdom. *Hum Vaccines Immunother.* 2015;11(5):1153-56. **PubMed | Google Scholar**
7. Yang JD, Gyedu A, Afihene MY, Duduyemi BM, Micah E, Kingham TP *et al.* Hepatocellular carcinoma occurs at an earlier age in Africans, particularly in association with chronic hepatitis B. *Am J Gastroenterol.* 2015 Nov;110(11):1629-31. **PubMed | Google Scholar**
8. Kao J-H. Hepatitis B vaccination and prevention of hepatocellular carcinoma. *Best Pract Res Clin Gastroenterol.* 2015 Dec; 29(6): 907-17. **PubMed | Google Scholar**
9. Chang M-H. Hepatitis B virus infection. *Semin Fetal Neonatal Med.* 2007;12(3):160-167. **Google Scholar**
10. Ofori-Asenso R, Agyeman AA. Hepatitis B in Ghana: a systematic review and meta-analysis of prevalence studies (1995-2015). *BMC Infect Dis.* 2016;16(1):130. **PubMed | Google Scholar**
11. Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. *Lancet.* 2015;386(10003):1546-1555. **PubMed | Google Scholar**
12. Awuku YA, Yeboah-Afihene M. Hepatitis B at-birth dose vaccine: an urgent call for implementation in Ghana. *Vaccines.* 2018;6(1):15. **PubMed | Google Scholar**
13. World Health Organization. Hepatitis B control through immunization: a reference guide. 2014.
14. Beasley RP, Lee GC-Y, Roan C-H, Hwang L-Y, Lan C-C, Huang F-Y *et al.* Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine. *Lancet.* 1983 Nov 12;2(8359):1099-102. **PubMed | Google Scholar**
15. Mele A, Tancredi F, Romanò L, Giuseppone A, Colucci M, Sangiuolo A *et al.* Effectiveness of hepatitis B vaccination in babies born to hepatitis B surface antigen-positive mothers in Italy. *J Infect Dis.* 2001;184(7):905-8. **PubMed | Google Scholar**
16. Beasley RP, Trepo C, Stevens CE, Szmuness W, Beasley RP. The e antigen and vertical transmission of hepatitis B surface antigen. *Am J Epidemiol Hyg Public Heal.* 1977;105(2):94-98. **PubMed | Google Scholar**
17. Pan CQ, Duan ZP, Bhamidimarri KR, Zou HB, Liang XF, Li J, Tong MJ *et al.* An algorithm for risk assessment and intervention of mother to child transmission of hepatitis B virus. *Clin Gastroenterol Hepatol.* 2012 May;10(5):452-9. **PubMed | Google Scholar**

18. Zhang Z, Li A, Xiao X. Risk factors for intrauterine infection with hepatitis B virus. *Int J Gynecol Obstet.* 2014;125(2): 158-161. **PubMed | Google Scholar**

19. Pujol FH, Navas MC, Hainaut P, Chemin I. Worldwide genetic diversity of HBV genotypes and risk of hepatocellular carcinoma. *Cancer Lett.* 2009;286(1):80-8. **PubMed | Google Scholar**

20. Liu C-J, Kao J-H. Global perspective on the natural history of chronic hepatitis B: role of hepatitis B virus genotypes A to J. *Semin Liver Dis.* 2013;33(2):97-102. **PubMed | Google Scholar**

21. Sunbul M. Hepatitis B virus genotypes: global distribution and clinical importance. *World J Gastroenterol.* 2014 May 14;20(18):5427-34. **PubMed | Google Scholar**

22. Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation study of the number of events per variable in logistic regression analysis. *J Clin Epidemiol.* 1996;49(12):1373-9. **PubMed | Google Scholar**

23. Candotti D, Danso K, Allain J-P. Maternofetal transmission of hepatitis B virus genotype E in Ghana, West Africa. *J Gen Virol.* 2007;88(10):2686-95. **PubMed | Google Scholar**

24. Amidu N, Alhassan A, Obirikorang C, Feglo P, Majeed SF, Timmy-Donkoh E *et al.* Sero-prevalence of hepatitis B surface (HBsAg) antigen in three densely populated communities in Kumasi, Ghana. *J Med Biomed Sci.* 2012;1(2):59-65. **Google Scholar**

25. Martinson FEA, Weigle KA, Royce RA, Weber DJ, Suchindran CM, Lemon SM. Risk factors for horizontal transmission of hepatitis B virus in a rural district in Ghana. *Am J Epidemiol.* 1998 Mar 1;147(5):478-87. **PubMed | Google Scholar**

26. Dumpis U, Holmes EC, Mendy M, Hill A, Thursz M, Hall A *et al.* Transmission of hepatitis B virus infection in Gambian families revealed by phylogenetic analysis. *J Hepatol.* 2001;35(1):99-104. **PubMed | Google Scholar**

27. Andernach IE, Hü Bschen JM, Muller CP. Hepatitis B virus: the genotype E puzzle. *Rev Med Virol.* 2009 Jul;19(4):231-40. **PubMed | Google Scholar**

28. Tacke F, Amini-Bavil-Olyae S, Heim A, Luedde T, Manns MP, Trautwein C. Acute hepatitis B virus infection by genotype F despite successful vaccination in an immune-competent German patient. *J Clin Virol.* 2007;38(4):353-7. **PubMed | Google Scholar**

Table 1: general characteristics of the mothers and infants included in the study and the birth context, n=51

Mother's age (years)		Birth Context	
Parameter	Value (SD)	Birth type	Number of cases (%)
Mean age	31.2(4.6)	Home	0(0)
Median age	31.5	Hospital	51(100)
Minimum	23	Vaginal	32(62.7)
Maximum	40	Caesarean	19(37.3)
Infant's age (months)			
Parameter	Value (SD)		
Mean age	13.5(4.8)		
Median age	15		
Minimum	6		
Maximum	22		

Table 2: proportion of infants who were vaccinated and received prophylactic interventions, as well as mothers who received antiviral therapy during pregnancy

Clinical Intervention	Number of cases (%)
Vaccinated	
Yes	49(96.1)
No	2(3.9)
Vaccine birth dose[†]	
Yes	32(66.7)
No	16(33.3)
Vaccine type	
Monovalent	3(6.1)
Pentavalent	17(34.7)
Both	29(59.2)
PVST	
Yes	0(0)
No	49(100)
HBIG administered[†]	
Yes	30(60.0)
No	20(40.0)
Antiviral therapy	
Yes	1(2.0)
No	50(98.0)

*one case uncertain whether vaccination was administered within the first 24hrs
†one case uncertain whether HBIG was administered

Table 3: hepatitis B viral marker testing rates and results of mothers during pregnancy

Viral marker testing	
Testing	Number of Cases (%)
HBeAg tested^{**}	
Yes	3(6.0)
No	47(94.0)
HBeAg result[*]	
Positive	3(100)
Negative	0(0)
HBV DNA tested	
Yes	1 (2.0)
No	50 (98.0)
HBV DNA result	
<20 IU/ml	1(100)

*HBeAg tests were performed after delivery
†one case uncertain whether HBeAg testing was performed

Table 4: contingency tables and Fisher's exact test of factors related to HBV mother-to-child transmission

Variable	HBsAg (-)	HBsAg (+)	p-value
Birth type			0.29
Vaginal	29	3	
Caesarean	19	0	
Vaccinated			1.00
Yes	46	3	
No	2	0	
Vaccine birth dose			0.25
Yes	31	1	
No	14	2	
HBIG administered			0.06
Yes	30	0	
No	17	3	
Antiviral therapy			1.00
Yes	1	0	
No	47	3	